Business Of Biotech
The Business Of CNS with Acumen's Jim Doherty, Ph.D.
Jan 27, 2025
Jim Doherty, President and Chief Development Officer at Acumen Pharmaceuticals, shares his extensive experience in developing therapies for CNS diseases. He discusses the historical challenges of Alzheimer’s treatment, the controversies over new amyloid-targeting drugs, and the pivotal role of biomarkers in personalized medicine. Highlighting Acumen's promising candidate, Sobernatug, he reveals its innovative approach to targeting soluble A-beta oligomers, while emphasizing the importance of collaboration and evolving strategies in CNS drug development.
47:51
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Dr. Jim Doherty highlights the critical advancements in Alzheimer's therapeutics, emphasizing the significance of recent drug approvals after a prolonged stagnation in the field.
- Acumen Pharmaceuticals seeks to innovate in CNS treatments by using Sobernatug to target soluble amyloid oligomers, aiming for improved patient outcomes and administration methods.
Deep dives
Dr. Jim Doherty's Commitment to Neuroscience
Dr. Jim Doherty has dedicated his career to developing new therapeutics for various brain disorders, driven by the significant unmet need in the central nervous system (CNS) field. He emphasizes the vast range of conditions that require innovative treatments, including neurodegenerative diseases like Alzheimer's, seizure disorders, and psychiatric conditions such as major depression. His longstanding interest in brain health stems from the complex challenges these disorders present, as well as the potential to positively impact the lives of patients. Throughout his career, the advancements in therapeutic modalities, such as large molecules and genetic therapies, have fueled his motivation to continue working in neuroscience.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
